{'fraction_non_alphanumeric': 0.05411350637923449, 'fraction_numerical': 0.04355477342718874, 'mean_word_length': 4.8307692307692305, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MICROALBUMINURIA AND CARDIOVASCULAR DISEASE IN HYPERTENSIVE PATIENTS INCLUDED IN THE IBERICAN STUDY

Objective: The general aim of IBERICAN study is to know the prevalence and incidence of cardiovascular risk factors and cardiovascular and renal disease in Spain. The aim of this abstract is to know the prevalence of microalbuminuria and its relation with cardiovascular disease in the hypertensive patients of the IBERICAN Study Design and method: The IBERICAN Study is a longitudinal, observational, and multicentric study with subjects between 18 to 85 years of age, recruited in Primary Care and who will be follow up at least 5 years. The final sample size is estimated in 7.000 patients. We show the baseline characteristics of the patients in the first visit (n = 5.944). In this abstract, we analyzed patients with microalbuminuria and we analyzed their association with the presence of cardiovascular disease. Microalbuminuria was defined as a albumin/creatinine ratio between 30 and 299 mg/g, according to the Guide KDIGO 2012. The established cardiovascular disease were: ischemic heart disease, stroke, heart failure, peripheral arterial disease. We also analyze the presence of atrial fibrillation. Results: 2.873 hypertensive patients (prevalence: 48.3%), the mean age in the sample was 64.7 ± 12 years, 49.7% women, antiquity of hypertension 9.7 ± 6 years, BMI 31.1 ± 8.9 kg/m2. Prevalence of microalbuminuria in hypertensive patiens: 11.7%. Prevalence of cardiovascular disease was: 23,8%;, ischemic heart disease 10.4%, stroke 5.5%, peripheral arterial disease 7%, and heart failure 5.6%. The prevalence of microalbuminuria in relation to the presence of each of the cardiovascular disease, regarding his absence was: ischemic heart disease 15.6% vs. 9.6%, p < 0.01; stroke 8.8% vs 5.1%, p < 0.05; heart failure 7.8% vs. 5.2%, p = NS; peripheral arterial disease 13.2% vs. 6.1%, p < 0.001; atrial fibrillation 13.6% vs. 7.8%, p < 0.001. Conclusions: The population of hypertensive patients of the IBERICAN study has a prevalence of microalbuminuria of 11%. This prevalence is higher, statistically significantly, in the presence of cardiovascular disease: ischemic heart disease, stroke, heart failure, peripheral arterial disease and atrial fibrillation.